Technology evaluation: omalizumab, Genentech/Novartis/Tanox.
Genentech, Novartis and Tanox have co-developed Genentech's anti-IgE humanized monoclonal antibody omalizumab for the treatment of allergic rhinitis and asthma. The antibody is currently undergoing phase II clinical trials for allergic rhinitis in Canada and phase III clinical trials for both indications in Japan. Omalizumab is at the pre-registration stage for both indications in the US, New Zealand, Switzerland and Western Europe, and is currently registered for both indications in Australia.
Lazaar
Aili L
AL
University of Pennsylvania Medical Center, Pulmonary, Allergy and Critical Care Division, 852 BRB II/III, 421 Curie Boulevard, Philadelphia, PA 19104-6160, USA. alazaar@mail.med.upenn.edu
D018926:Anti-Allergic Agents / Q000097:blood / Q000627:therapeutic use; D018927:Anti-Asthmatic Agents / Q000097:blood / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001249:Asthma / Q000188:drug therapy; D002986:Clinical Trials as Topic; D006801:Humans; D000069444:Omalizumab; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy
D018926:Anti-Allergic Agents; D018927:Anti-Asthmatic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab